Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will hold one-on-one investor meetings at the Lake Street Capital Markets "BIG10" Conference in New York City on September 10, 2026.
The event runs in a one-on-one meeting format only. Profound will not offer a webcast, so investors who want access to management must attend the meetings in person.
Profound Medical sells interventional MRI therapies built around two platforms
The commercial-stage medical device company develops and markets interventional MRI (iMRI) procedures. Its flagship platform, TULSA-PRO, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure to see, ablate and confirm therapy in real time. The approach covers treatment from whole-gland to subtotal, hemi, multifocal and focal ablation.
Profound also commercializes Sonalleve, an MRI-guided therapy for pain palliation of bone metastases, desmoid tumors and osteoid osteoma. It is also used for uterine fibroids and adenomyosis. In gynecologic applications, Sonalleve enables uterine-sparing treatment that may help preserve fertility. The company is exploring further uses, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
TULSA-PRO holds FDA clearance and approvals in at least six other jurisdictions
The U.S. FDA has cleared TULSA-PRO for transurethral ultrasound ablation (TULSA) of prostate tissue. The system is also cleared in Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the UAE.
The FDA approved Sonalleve as a Humanitarian Device Exemption (HDE) in the United States for treating osteoid osteomas in the extremities. Sonalleve is also cleared or approved in Europe, Canada, China and Saudi Arabia.